## METROPOLITAN HEALTH NETWORKS INC

Form 10-Q August 08, 2006

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM	10-Q
X  QUARTERLY REPORT PURSUANT TO SECURITIES EXCHA	
For the quarterly perio	d ended June 30, 2006
OR	
_  TRANSITION REPORT PURSUANT TO SECURITIES EXCHA	
For the transition period from	to
Commission file n	umber: 001-32361
METROPOLITAN HEALT (Exact name of registrant as	•
Florida (State or other jurisdiction of incorporation or organization)	65-063574 (I.R.S. Employer Identification No.)
250 Australian Avenue, Suite 400 West Palm Beach, FL (Address of principal executive offices)	33401 (Zip Code)
(561) 805-8500 telephone number, in	-
Non (Former name, former address and fo last re	rmer fiscal year, if changed since
Indicate by check mark whether the regist to be filed by Section 13 or 15(d) of the the preceding 12 months (or for such sh required to file such reports), and ( requirements for t	Securities Exchange Act of 1934 during orter period that the registrant was 2) has been subject to such filing
Yes [X]	No [_]
Indicate by check mark whether the reg an accelerated filer, or a non-acc "accelerated filer and large acce the Excha	elerated filer. See definition of lerated filer" in Rule 12b-2 of
Large accelerated filer [_] Accelerated	filer [X] Non-accelerated filer [_]
Indicateby check mark whether the regist Rule 12b-2 of the	

Yes [\_] No [X]

Indicate the number of shares outstanding of each of the issuer's classes of common stock, as of the latest practicable date.

Class Outstanding at July 31, 2006

Common Stock, \$.001 par value per share 50,106,526 shares

## METROPOLITAN HEALTH NETWORKS, INC.

## INDEX

Part	I.	FINANCIAL INFORMATION	Page
Item	1.	Condensed Consolidated Financial Statements (Unaudited):	
		Condensed Consolidated Balance Sheets as of June 30, 2006 and December 31, 2005	4
		Condensed Consolidated Statements of Operations for the Three and Six Months Ended June 30, 2006 and 2005	5
		Condensed Consolidated Statements of Cash Flows for the Six Months Ended June 30, 2006 and 2005	6
		Notes to Condensed Consolidated Financial Statements	7-17
Item	2.	Management's Discussion and Analysis of Financial Condition and Results of Operations	18-28
Item	3.	Quantitative and Qualitative Disclosures About Market Risk	28-29
Item	4.	Controls and Procedures	29
PART	II.	OTHER INFORMATION	
Item	1.	Legal Proceedings	30
Item	1A.	Risk Factors	30
Item	2.	Changes in Securities and Use of Proceeds	30
Item	3.	Default Upon Senior Securities	30
Item	4.	Submission of Matters to a Vote of Security Holders	30-31
Item	5.	Other Information	31
Item	6.	Exhibits	31-32
SIGNA	ATURES		33

2

PART 1. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

3

## METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED BALANCE SHEETS

\_\_\_\_\_\_

	·	JUNE 30, 2006 (UNAUDITED)		MBER 31, 2005 (AUDITED)
ASSET	S			
CURRENT ASSETS Cash and equivalents	\$	15,633,283	\$	15,572,862
Short-term investments  Accounts receivable, net of allowance		5,677,050		
		5,155,658		4,183,974
Inventory		241,263		201,430
prepaid expenses		1,070,721		473,286
Deferred income taxes		3,400,000		3,500,000
Other current assets		251,082		547,976
TOTAL CURRENT ASSETS		31,429,057		24,479,528
PROPERTY AND EQUIPMENT, net		1,139,907		899,998
INVESTMENTS		940,757		627,819
GOODWILL, net		1,992,133		1,992,133
DEFERRED INCOME TAXES		3,680,000		4,493,000
OTHER ASSETS		1,012,774		622,628
TOTAL ASSETS	\$	40,194,628	\$	
LIABILITIES AND STOC				
CURRENT LIABILITIES Accounts payable	\$	645,831	\$	969,184

Advance and unearned premiums	3,337,226	
Estimated medical expenses payable	2,601,708	694,410
Accrued payroll and payroll taxes	1,147,750	1,459,098
Accrued expenses	742,980	293 <b>,</b> 552
TOTAL CURRENT LIABILITIES	 	 
	 8,475,495 	3,416,244
COMMITMENTS AND CONTINGENCIES		
STOCKHOLDERS' EQUITY  Preferred stock, par value \$.001 per share; stated value \$100 per share; 10,000,000 shares authorized; 5,000 issued and outstanding  Common stock, par value \$.001 per share; 80,000,000 shares authorized; 50,106,526 and 49,851,526 issued and outstanding, respectively	500,000	500,000
Additional paid-in capital	50,106	49,851
Accumulated deficit	40,712,061 (9,543,034)	40,182,889 (11,033,878)
TOTAL STOCKHOLDERS' EQUITY	 31,719,133	 29,698,862
TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY	40,194,628	33,115,106

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

4

## METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

\_\_\_\_\_\_

	FOR THE SIX MONTHS 2006 (UNAUDITED)	E ENDED JUNE 30, 2005 (UNAUDITED)	FOR THE THREE MONTHS 2006 (UNAUDITED)	ENDED JUN 2005 (UNAUDIT
REVENUES, net	\$ 112,981,144	\$ 91,688,772	\$ 57,547,610	\$ 46 <b>,</b> 16

OPERATING EXPENSES

Direct medical costs Other medical costs		95,297,419		77,332,404		48,334,576		38 <b>,</b> 79
		5,144,944		5,210,820		2,559,277		2,57
Total medical expenses		100,442,363		82,543,224		50,893,853		41,37
Administrative payroll, payroll taxes andbenefits Marketing and advertising		5,003,185		2,682,290		2,555,386		1,41
General and administrative		1,995,854		156 <b>,</b> 189		1,021,924		15
General and administrative		3,549,237		2,739,344		1,977,221		1,37
TOTAL EXPENSES		110,990,639		88,121,047		56,448,384		44,31
OPERATING INCOME		1,990,505		3,567,725		1,099,226		1,85
OTHER INCOME								
Interest income, net Other		412,138 1,201		137,049 129,614		222 <b>,</b> 700 21		7 6
TOTAL OTHER INCOME								
TOTAL OTHER INCOME		413,339		266,663		222 <b>,</b> 721		13
INCOME BEFORE INCOME TAXES		2,403,844		3,834,388		1,321,947		1,99
INCOME TAXES		(913,000)		(1,447,000)		(502,800)		(75
NET INCOME	\$	1,490,844	\$	2,387,388	\$	819 <b>,</b> 147	\$	1,24 =====
NET EARNINGS PER SHARE: Basic	\$	0.03				0.02	\$	
Diluted	\$	0.03	=== \$	0.05	\$	0.02	\$	======
	====		===		===		===	

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

5

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

-----

						_
	20	006		20	005	
FOR	THE	SIX	MONTHS	ENDED	JUNE	

CASH FLOWS FROM OPERATING ACTIVITIES:				
Net income	\$	1,490,844	\$	2,387,38
Adjustments to reconcile net income to				
net cash provided by operating activities:				
Depreciation and amortization		214,973		164,97
Deferred income taxes		913,000		870,00
Stock-based compensation expense		363,502		0,0,00
Tax benefit on exercise of stock options		363,302		577 <b>,</b> 00
				5//,00
Loss on disposal of assets		103		- 00 35
Amortization of securities issued for professional services Changes in operating assets and liabilities:		26,175		88 <b>,</b> 37
Accounts receivable, net		(971 <b>,</b> 684)		(2,125,98
Inventory		(39,833)		17 <b>,</b> 87
Prepaid expenses		(597 <b>,</b> 435)		(549 <b>,</b> 78
Other current assets		296,895		236,62
Other assets		3,367		(287,94
Accounts payable		(323,352)		(294,25
Advance and unearned premiums		3,337,226		-
Estimated medical expenses payable		1,907,298		_
Accrued payroll		(311,348)		(619,51
Accrued expenses		449,427		467,30
Total adjustments		5,268,314		(1,455,35
Net cash provided by operating activities		6,759,158		932 <b>,</b> 03
CASH FLOWS FROM INVESTING ACTIVITIES: Short-term investments		(5,677,050)		1 500 00
Investments		(312,938)		(601,78
Pedemption of restricted certificates of deposit		(312,930)		1,000,00
Capital expenditures		(848, 499)		(160,32
Net cash (used in)/provided by investing activities		(6,838,487)		1,737,89
CASH FLOWS FROM FINANCING ACTIVITIES:				
Repayments on notes payable				(991,00
Repurchase of warrants				(85,00
Proceeds from exercise of stock options and warrants		139,750		384,43
Net proceeds from issuance of common stock				134,75
Net cash provided by/(used in) financing activities		139,750		
NET INCREASE IN CASH AND EQUIVALENTS		60,421		2,113,1
CASH AND EQUIVALENTS - BEGINNING		15,572,862		11,344,1
CASH AND EQUIVALENTS - ENDING	\$	15,633,283		
	==	========	==:	

The accompanying notes are an integral part of these Condensed Consolidated Financial Statements.

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

\_\_\_\_\_\_

#### NOTE 1. BASIS OF PRESENTATION AND SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES

\_\_\_\_\_\_

The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not include all of the information and footnotes required by accounting principles generally accepted in the United States of America for complete financial statements. In the opinion of management, all adjustments considered necessary for a fair presentation have been included and such adjustments are of a normal recurring nature. Operating results for the three and six months ended June 30, 2006 are not necessarily indicative of the results that may be expected for the year ending December 31, 2006.

The audited financial statements at December 31, 2005, which were included in the Company's Form 10-K filed on March 16, 2006, should be read in conjunction with these condensed consolidated financial statements.

Unless otherwise indicated or the context requires, all references in this Form 10-Q to the "Company" refers to Metropolitan Health Networks, Inc. and its consolidated subsidiaries.

#### SEGMENT REPORTING

The Company applies Financial Accounting Standards Boards ("FASB") Statement No. 131, "Disclosure about Segments of an Enterprise and Related Information." The Company has considered its operations and has determined that, in 2005, it operated, and continues to operate in 2006, in two segments for purposes of presenting financial information and evaluating performance, a Provider Service Network (managed care and direct medical services), operated through its wholly owned subsidiary, Metcare of Florida, Inc. (the "PSN"), and a Medicare Advantage HMO, operated through its wholly owned subsidiary Metcare Health Plans, Inc. (the "HMO").

As such, the accompanying financial statements present information in a format that is consistent with the financial information used by management for internal use. See "Note 6. Business Segment Information" for additional information regarding the Company's business segments.

#### CASH AND EQUIVALENTS

The Company considers all highly liquid investments with original maturities of three months or less to be cash equivalents. From time to time, the Company maintains cash balances with financial institutions in excess of federally insured limits.

#### SHORT-TERM INVESTMENTS

All investments with original maturities of greater than 90 days are accounted for in accordance with Statement of Financial Accounting Standards ("SFAS") No. 115, "Accounting for Certain Investments in Debt and Equity Securities." The Company determines the appropriate classification at the time of purchase. As of June 30, 2006, the Company's short-term investments consisted of commercial paper and certificates of deposit classified as

available-for-sale. All income generated from these short-term investments during the three and six months ended June 30, 2006 was recorded as interest income.

#### LONG-TERM INVESTMENTS

Long-term investments, which consist primarily of an equity interest in a non-assessable reciprocal insurance organization through which the Company has renewed its malpractice insurance, are carried at cost. If an impairment occurs that is not considered temporary, the investment will be written down to net realizable value. Also included in long-term investments were certain certificates of deposit with original maturities in excess of one year. All income generated from these long-term certificates of deposit during the three and six months ended June 30, 2006 was recorded as interest income.

7

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

#### INCOME TAXES

The Company accounts for income taxes pursuant to Statement of Financial Accounting Standards No. 109, "Accounting for Income Taxes" ("SFAS 109"), which requires income taxes to be accounted for under the asset and liability method. Under this method, deferred income tax assets and liabilities are determined based upon differences between the financial statement carrying amounts of existing assets and liabilities and their respective tax bases using enacted tax rates in effect for the year in which the differences are expected to reverse. The effect on deferred tax assets and liabilities of a change in tax rates is recognized in earnings in the period that includes the enactment date.

SFAS No. 109 requires a valuation allowance to reduce the deferred tax assets reported if, based on the weight of the evidence, it is more likely than not that some portion or all of the deferred tax assets will not be realized. After consideration of all the evidence, both positive and negative (including, among others, projections of future taxable income, current year net operating loss carryforward utilization and the Company's profitability in recent years), the Company determined that future realization of its deferred tax assets was more likely than not. In the event it is determined that it is more likely than not that the Company would not be able to realize all or part of its net deferred tax assets in the future, an adjustment to record a deferred tax asset valuation allowance would be charged to income in the period such determination would be made. Changes in deferred tax assets are reflected in the "Income Taxes" expense line of the Company's Condensed Consolidated Statements of Operations.

Due to the availability of deferred tax assets during the three and six months ended June 30, 2006, the Company has not recorded any amounts payable for U.S. federal income taxes and does not expect any cash outlay to be required in connection with the income tax provisions.

#### REVENUE RECOGNITION

The Company's PSN is a party to two managed care contracts with Humana, Inc. (the "Humana Agreements") and provides medical care to its patients through wholly-owned and contracted independent medical practices and providers (collectively, the "Affiliated Providers"). Accordingly, the PSN receives a

monthly fee for each patient that chooses one of the Affiliated Providers as his or her primary care physician in exchange for the PSN's assumption of responsibility for the provision of all necessary medical services to such patient, even those medical services not directly provided by one of the Affiliated Providers. Fees received by the PSN under these Humana Agreements are reported as revenues. The cost of both Affiliated Provider and non-Affiliated Provider services under these Humana Agreements are not included as a deduction to net revenues of the Company, but are reported as an operating expense. Changes in revenues resulting from the periodic changes in risk adjustment scores are recognized when the amounts become determinable and the collectibility is reasonably assured. In connection with the Humana Agreements, the Company is exposed to losses to the extent of the PSN's share of deficits, if any, on its Affiliated Providers. The PSN's share of deficits is 100% for Medicare Part A in the Central Florida market, 50% for Medicare Part A in the South Florida market and 100% for Medicare Part B in both the Central Florida and South Florida market. Revenues generated under the Humana Agreements accounted for approximately 88% and 99% of the Company's total revenues for the quarters ended June 30, 2006 and 2005, respectively, and approximately 90% and 99% of the Company's total revenues for the six months ended June 30, 2006 and 2005, respectively.

Humana may immediately terminate either of the Humana Agreements and/or any individual physician credentialed under the Humana Agreements, upon written notice, (i) if the PSN and/or any of its Affiliated Provider's continued participation may adversely affect the health, safety or welfare of any Humana member or bring Humana into disrepute; (ii) in the event of one of the PSN's physician's death or incompetence; (iii) if any of the PSN's physicians fail to meet Humana's credentialing criteria; (iv) in accordance with Humana's policies and procedures as specified in Humana's manual, (v) if the PSN engages in or acquiesces to any act of bankruptcy, receivership or reorganization; or (vi) if Humana loses its authority to do business in total or as to any limited segment or business (but only to that segment). The PSN and Humana may also terminate each of the Humana Agreements upon 90 days' prior written notice (with a 60 day opportunity to cure, if possible) in the event of the other's material breach of the applicable Humana Agreement.

8

## METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Failure to maintain the Humana Agreements on favorable terms, for any reason, would adversely affect the Company's results of operations and financial condition.

The Company also recognizes non-Humana fee-for-service revenues, net of contractual allowances, as medical services are provided to patients by the Company's wholly-owned medical practices. These services are typically billed to patients, Medicare, Medicaid, health maintenance organizations and insurance companies. The Company provides an allowance for uncollectible amounts and for contractual adjustments relating to the difference between standard charges and agreed upon rates paid by certain third party payers.

Effective July 1, 2005 the Company had the requisite Florida and federal licenses, approvals and contract to begin marketing, enrolling and providing services to Medicare beneficiaries through its own Medicare Advantage HMO. The contract with the Centers for Medicare and Medicaid Services ("CMS")

renews on an annual basis. The HMO receives a monthly premium for each enrollee in its plan and is responsible for the provision of all covered medical services for that enrollee. Premium revenues are recognized as income in the period members are entitled to receive services, and are net of retroactive membership adjustments. Retroactive membership adjustments result from enrollment changes not yet processed, or not yet reported by CMS. Changes in revenues from CMS resulting from the periodic changes in risk adjustment scores for the HMO's membership are recognized when the amounts become determinable and the collectibility is reasonably assured.

#### MARKETING AND ADVERTISING COSTS

Marketing and advertising costs are expensed as incurred. Marketing and advertising expense was approximately \$1.0 million and \$156,000 for the quarters ended June 30, 2006 and 2005, respectively, and \$2.0 million and \$156,000 for the six months ended June 30, 2006 and 2005, respectively.

#### RECLASSIFICATION

Certain amounts reported in the comparative financial statements have been reclassified to conform to the presentation for the period ended June 30, 2006.

#### USE OF ESTIMATES

Revenue, Expense and Receivables

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. The most significant area requiring estimates relates to the PSN's arrangements with Humana. Such estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.

With regard to revenues, expenses and receivables arising from the Humana Agreements, the Company estimates the amounts it believes will ultimately be realizable based in part upon estimates of claims incurred but not reported ("IBNR") and estimates of retroactive adjustments or unsettled costs to be applied by Humana. The IBNR estimates are made by Humana utilizing actuarial methods and are continually evaluated by management of the Company based upon its specific claims experience. It is reasonably possible that some or all of these estimates could change in the near term by an amount that could be material to the financial statements.

From time to time, Humana charges the PSN for certain medical expenses, which the Company believes are erroneous or are not supported by the Humana Agreements. Management's estimate of recovery on these contestations is based upon its judgment and its consideration of several factors including the nature of the contestations, historical recovery rates and other qualitative factors.

During 2005, the Company incurred approximately \$4.0 million of medical costs related to the implantation of certain Implantable Automatic Defibrillators ("AICD's"). CMS directed that the costs of certain of these procedures that met 2005 eligibility requirements be paid by CMS, rather than billed to Medicare Advantage plans. The Company is working with Humana and the related providers to secure reimbursement for these amounts, and estimated a recovery of approximately \$2.2 million at December 31, 2005. Approximately \$379,000 of this amount was collected during the six months ended June 30, 2006, while an additional \$500,000 was written off due to

revised guidance issued by CMS in July 2006 regarding the costs payable by CMS in connection with these procedures. Accordingly, related accounts receivable in the accompanying consolidated balance sheets were \$1.3 million and \$2.2 million at June 30, 2006 and December 31, 2005, respectively. It is reasonably possible that this estimate could change in the near term by an amount that could be material to the financial statements.

9

# METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Included in revenues for the quarter and six months ended June 30, 2006 were estimated amounts payable to the Company as a result of funding increases under the Medicare risk adjustment ("MRA") program. The purpose of the MRA program is to use health status indicators to improve the accuracy of payments and establish incentives for plans to enroll and treat less healthy Medicare beneficiaries. From 2000 to 2003, risk adjustment payments accounted for only 10% of the payment made by CMS to the Medicare health plans, with the remaining 90% based on demographic factors. In 2004 and 2005, the percentage of payment attributable to risk adjustment was increased to 30% and 50%, respectively. The percentage of payment attributable to risk has increased to 75% in 2006, with the 100% phase-in of risk-adjusted payment anticipated to be completed in 2007. Based on the Company's applicable risk scores, the Company accrued approximately \$3.5 million during the six months ended June 30, 2006 related to incremental revenues anticipated to be received as a result of the MRA funding increases. These amounts, which are included in accounts receivable in the accompanying consolidated balance sheets at June 30, 2006, are expected to be received by the Company in the second half of the year, consistent with the timing of prior year payments. It is reasonably possible that this estimate could change in the near term by an amount that could be material to the financial statements.

Non-Humana fee-for-service accounts receivable, aggregating to approximately \$1,145,000 and \$797,000 at June 30, 2006 and December 31, 2005, respectively, relate principally to medical services provided on a non-capitated basis, and are reduced by amounts estimated to be uncollectible (approximately \$755,000 and \$555,000 at June 30, 2006 and December 31, 2005, respectively). Management's estimate of uncollectible amounts is based upon its analysis of historical collections and other qualitative factors, however it is possible the Company's estimate of uncollectible amounts could change in the near term. In addition, accounts receivable at June 30, 2006 and December 31, 2005 includes approximately \$299,000 and \$159,000, respectively, due to the HMO from CMS and HMO enrollees.

With regards to the HMO, the cost of medical benefits is recognized in the period in which services are provided and includes an IBNR estimate based on management's best estimate of medical benefits payable. It is reasonably possible that some or all of these estimates could change in the near term by an amount that could be material to the financial statements.

The HMO memberships' average risk adjustment factor declined from December 2005 to June 2006 as a result of a large influx of new members in 2006. This decline resulted in decreased average member monthly premiums. The Company believes that the actual average risk adjustment factor for its population during this period was higher and that an increase will be reflected as claims and health data for these new members are entered into the CMS

system, which is expected to result in retroactive premium adjustments. The Company cannot estimate the amount of the anticipated increase at this time but believes this amount may be material to the results of the HMO.

Accounting for Prescription Drug Benefits under Medicare Part D

On January 1, 2006, the HMO and the PSN, through the Humana Agreements, began covering prescription drug benefits in accordance with the requirements of Medicare Part D, to the HMO's and PSN's Medicare Advantage members. The benefits covered under Medicare Part D are in addition to the benefits covered by the HMO and the PSN under Medicare Parts A and B.

In general, pursuant to Medicare Part D, pharmacy benefits may vary in terms of coverage levels and out-of-pocket costs for beneficiary premiums, deductibles and co-insurance. However, all Part D plans must offer either "standard coverage" or its actuarial equivalent (with out-of-pocket threshold and deductible amounts that do not exceed those of standard coverage). These "defined standard" benefits represent the minimum level of benefits mandated by Congress. In addition to defined standard plans offered by the HMO, the PSN, through the Humana Agreements, offers prescription drug plans containing benefits in excess of the standard coverage limits.

The payment the Company's HMO receives monthly from CMS generally represents its bid amount for providing insurance coverage. The Company recognizes premium revenue for providing this insurance coverage ratably over the term of its annual contract. However, its CMS payment is subject to 1) risk corridor adjustments and 2) subsidies in order for the HMO and CMS to share the risk associated with financing the ultimate costs of the Part D benefit.

10

## METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

The amount of revenue payable to a plan by CMS is subject to adjustment, positive or negative, based upon the application of risk corridors that compare a plan's revenues targeted in their bids ("target amount') to actual prescription drug costs. Variances exceeding certain thresholds may result in CMS making additional payments to the HMO or require the HMO to refund to CMS a portion of the payments it received. Actual prescription drug costs subject to risk sharing with CMS are limited to the costs that are, or would have been, incurred under the CMS "defined standard" benefit plan ("allowable risk corridor costs"). The Company estimates and recognizes an adjustment to premium revenues related to the risk corridor payment adjustment based upon pharmacy claims experience to date as if the annual contract were to end at the end of each reporting period. Accordingly, this estimate provides no consideration to future pharmacy claims experience. It is reasonably possible that this estimate could change in the near term by an amount that could be material.

Certain subsidies represent reimbursements from CMS for claims the HMO paid for which it assumes no risk, including reinsurance payments and low-income cost subsidies. Claims paid above the out-of-pocket or catastrophic threshold for which the HMO is not at risk are all reimbursed by CMS through the reinsurance subsidy plans. Low-income cost subsidies represent reimbursements from CMS for all or a portion of the deductible, the coinsurance and the co-payment amounts for low-income beneficiaries. The Company accounts for these subsidies as current liabilities in its balance

sheet and as an operating activity in its statement of cash flows. The Company does not recognize premium revenue or claims expense for these subsidies.

The HMO recognizes pharmacy benefit costs as incurred. It has subcontracted the pharmacy claims administration to a third party pharmacy benefit manager.

With regards to the PSN, the Company receives Medicare Part D revenue pursuant to the applicable percent of premium provided for in the Humana Agreements. Humana does not provide the Company with a separate accounting for Part D premium and expense. As with its HMO, the Company recognizes pharmacy benefit costs as such costs are incurred by the PSN. With regards to the estimated amount of any risk corridor adjustments, the Company has relied upon estimates provided by Humana to the Company and has recorded a downward adjustment to premium revenue based on these estimates. It is reasonably possible that this estimate could change in the near term by an amount that could be material.

#### Deferred Tax Asset

The Company has recorded a deferred tax asset of approximately \$7.1 million at June 30, 2006. Realization of the deferred tax asset is dependent on generating sufficient taxable income in the future. The amount of the deferred tax asset considered realizable could change in the near term if estimates of future taxable income are modified and those changes could be material.

#### ACCOUNTS RECEIVABLE

Accounts receivable at June 30, 2006 and December 31, 2005 were as follows:

	JUN	IE 30, 2006	DECEN	MBER 31, 2005
Humana accounts receivable, net	\$	4,467,000	\$	3,782,000
Non-Humana accounts receivable, net		689,000		402,000
Accounts receivable, net	\$	5,156,000	\$	4,184,000
			=====	

#### EARNINGS PER SHARE

The Company applies Statement of Financial Accounting Standards No. 128, "Earnings Per Share" ("SFAS 128") which requires presentation of both basic net income per share and diluted net income per share. Basic earnings per share is computed using the weighted average number of common shares outstanding during the period. Diluted earnings per share is computed using the weighted average number of common shares outstanding during the period adjusted for incremental shares attributed to outstanding options and warrants, convertible debt and preferred stock convertible into shares of common stock.

NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

	OR THE SIX MONT 2006	DED JUNE 30, 2005	FO:	R THE 20
Net Income	\$ 1,491,000	\$ 2,387,000	\$	
Less: Preferred stock dividend	(25,000)	(25,000)		
Income available to common shareholders	\$ 1,466,000	\$ 2,362,000	\$	
Denominator:	 	 		
Weighted average common shares outstanding		48,435,000		49
Basic earnings per common share	\$	\$ 0.05	\$	
Income available to common shareholders		2,362,000		====
Denominator:				
	49,916,000	48,435,000		49
Common share equivalents of outstanding stock: Options and warrants	 1,356,000			1
Weighted average common shares outstanding				
Diluted earnings per common share	\$ 0.03	\$ 0.05	\$	=====

#### NEW ACCOUNTING PRONOUNCEMENTS

In November 2004, the Financial Accounting Standards Board ("FASB") issued Statement of Financial Accounting Standards No. 151, "Inventory Costs" ("SFAS No. 151"), which is effective for fiscal periods beginning after June 15, 2005. This statement clarifies the accounting for abnormal amounts of idle facility expense, freight, handling costs, and wasted material. These items are required to be recognized as current period charges regardless of whether they meet the criterion of "so abnormal." The adoption of SFAS No. 151 did not have a material impact on the Company's financial statements.

In December 2004, the FASB issued Statement of Financial Accounting Standards No. 153, "Exchange of Non-Monetary Assets" ("SFAS No. 153"), which is effective for fiscal periods beginning after June 15, 2005. In the past, the net book value of the assets relinquished in a non-monetary transaction was used to measure the value of the assets exchanged. Under SFAS No. 153, assets exchanged in a non-monetary transaction will be at fair value instead of the net book value of the asset relinquished, as long as the transaction has commercial substance and the fair value of the assets exchanged is determinable within reasonable limits. The adoption of SFAS No. 153 did not have a material effect on the Company's financial statements.

SFAS No. 154, Accounting Changes and Error Corrections, was issued in May 2005 and replaces APB Opinion No. 20 (Accounting Changes) and SFAS No. 3 (Reporting Accounting Changes in Interim Financial Statements). SFAS No. 154 requires retrospective application for voluntary changes in accounting principle in most instances and is required to be applied to all accounting changes made in fiscal years beginning after December 15, 2005. The Company adopted SFAS No. 154 on January 1, 2006 and it did not have a material impact on the Company's consolidated financial condition or results of operations.

In July 2006, the FASB issued FASB Interpretation No. 48, "Accounting for Uncertainty in Income Taxes-an Interpretation of FASB Statement 109", or FIN 48. FIN 48 prescribes a comprehensive model for how a company should recognize, measure, present, and disclose in its financial statements uncertain tax positions that the company has taken or expects to take on a tax return. FIN 48 also revises disclosure requirements and introduces a prescriptive, annual, tabular roll-forward of the unrecognized tax benefits. FIN 48, which will become effective for the Company beginning January 1, 2007, requires the change in net assets that results from the application of the new accounting model to be reflected as an adjustment to retained earnings. The Company currently is evaluating the impact of adopting FIN 48.

12

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

\_\_\_\_\_\_

NOTE 2. DEBT

\_\_\_\_\_\_

On May 6, 2005 the Company executed an unsecured commercial line of credit agreement with a bank, which provided for borrowings and issuance of letters of credit of up to \$1.0 million. The credit line expired on March 31, 2006 and was automatically renewed with a new expiration date of March 31, 2007. The outstanding balance, if any, bears interest at the bank's prime rate. The credit facility requires the Company to comply with certain financial covenants, including a minimum liquidity requirement of \$2.0 million. The availability under the line of credit secures a \$1.0 million letter of credit that the Company has caused to be issued in favor of Humana. As of June 30, 2006, the Company has not utilized this commercial line of credit.

\_\_\_\_\_\_

#### NOTE 3. STOCK BASED COMPENSATION

-----

The Company has three stock option plans that are administered by the Compensation Committee of the Board of Directors. The 2001 Stock Option Plan and the Supplemental Stock Option Plan have 1,110,110 and 1,365,400 outstanding options granted under the plans, respectively, as of June 30, 2006. The Company does not intend to issue additional options from either plan in the future. The Omnibus Equity Compensation Plan (the "Omnibus Plan") provides for the grant of non-qualified or incentive stock options and other stock based awards to directors, executives and key employees of the Company, as well as to any other persons approved by the Compensation Committee. A total of 6,000,000 shares of Metropolitan's common stock are authorized for issuance pursuant the Omnibus Plan. As of June 30, 2006, options granted pursuant to the Omnibus Plan to purchase 2,780,033 shares of the Company's common stock are currently outstanding. Under the Omnibus

Plan, options are granted at the fair market value of the stock at the date of grant and expire no later than 10 years after the date of grant. Options granted under this Omnibus Plan generally vest over periods up to four years.

Prior to January 1, 2006, the Company followed Accounting Principles Board Opinion No. 25, ("APB No. 25"), "Accounting for Stock Issued to Employees," and related Interpretations in accounting for its employee stock options. Under APB No. 25, when the exercise price of the Company's employee stock options equaled or exceeded the market price of the underlying stock on the date of grant, no compensation expense was recognized. Stock options issued to independent contractors or consultants were accounted for in accordance with Statement of Financial Accounting Standards ("SFAS") No. 123, ("SFAS No. 123"), "Accounting for Stock-Based Compensation." For the quarter and six months ended June 30, 2005, no stock-based employee compensation expense was recognized in the accompanying condensed consolidated statement of income.

Effective January 1, 2006, the Company adopted SFAS No. 123(R) ("SFAS No. 123(R)"), "Share-Based Payment," which is a revision of SFAS No. 123, using the modified prospective transition method and therefore has not restated prior periods' results. Under the transition method, stock-based compensation expense for the first quarter of fiscal 2006 included compensation expense for all stock-based compensation awards granted prior to, but not yet vested as of, January 1, 2006, based on the grant date fair value estimated in accordance with the original provision of SFAS No. 123. Stock-based compensation expense for all share-based payment awards granted after January 1, 2006 is based on the grant-date fair value estimated in accordance with the provisions of SFAS No. 123(R). The Company recognizes these compensation costs net of an estimated forfeiture rate and recognizes the compensation costs for only those shares expected to vest. The Company calculates the fair value of employee stock options using a Black-Scholes option pricing model at the time the stock options are granted and that amount is amortized on a straight-line basis over the vesting period of the stock options, which is generally up to four years. The Company estimated the forfeiture rate based on its historical experience.

The fair value for employee stock options granted during the six months ended June 30, 2006 was calculated based on the following assumptions: risk-free interest rate from 4.80% to 4.99%; dividend yield of 0%; volatility factor of the expected market price of the Company's common stock of 50%; and expected option lives of two years. The expected life of the options is based on the historical exercise behavior of the Company's employees. The expected volatility factor is based on the historical volatility of the market price of the Company's common stock. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant.

13

METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

As a result of adopting SFAS No. 123(R) on January 1, 2006, for the quarter and six month periods ended June 30, 2006, the Company's income before income taxes was approximately \$162,000 and \$364,000 lower, respectively, and net income was lower by approximately \$101,000 and \$227,000, respectively, than if it had continued to account for share-based compensation under APB No. 25. The total income tax benefit recognized in

the income statement for share-based compensation was approximately \$61,000 and \$137,000 for the quarter and six month periods ended June 30, 2006. Basic and diluted earnings per share for the quarter and six months ended June 30, 2006 would have remained unchanged at \$.02 and \$.03, respectively, if the Company had not adopted SFAS No. 123(R).

SFAS No. 123(R) requires the tax benefits resulting from tax deductions in excess of the compensation cost recognized for options (excess tax benefits) to be classified as financing cash flows. For the quarter and six months ended June 30, 2006, the Company had net operating loss carryforwards and did not recognize any tax benefits resulting from the exercise of stock options because the related tax deductions would not have resulted in a reduction of income taxes payable. During the quarter and six months ended June 30, 2006, the Company issued 170,000 and 195,000 shares of common stock resulting from the exercise of stock options, respectively. Cash received from the option exercises was approximately \$131,000 and \$140,000 for the quarter and six months ended June 30, 2006.

The following table illustrates the effect on net income and earnings per share if the Company had applied the fair value recognition provisions of SFAS No. 123 for the quarter and six months ended June 30, 2005. For purposes of this pro forma disclosure, the fair value of these options were estimated at the date of grant using a Black-Scholes option pricing model based on the following assumptions for the quarter and six months ended June 30, 2005: risk-free interest rate from 2.82% to 4.24%; dividend yield of 0%; volatility factor of the expected market price of the Company's common stock of 50%; and expected option lives ranging from one to four and one-half years, depending on the vesting provisions of each option. The expected life of the options is based on the historical exercise behavior of the Company's employees. The expected volatility factor is based on the historical volatility of the market price of the Company's common stock. The risk-free rate for periods within the contractual life of the option is based on the U.S. Treasury yield curve in effect at the time of grant. The Company's proforma information follows:

		MONTHS ENDED UNE 30, 2005		
Net income, as reported  Less: Total stock-based employee compensation  expense determined under SFAS No. 123	\$	2,387,000	\$	1,243,000
for all awards, net of related tax		(482,000)		(219,000)
Pro forma net income	·	1,905,000	====	1,024,000
Earnings per share:				
Basic, as reported	\$	0.05	\$	0.03
Basic, pro forma	\$	0.04	\$	0.02
Diluted, as reported	\$	0.05		0.02
Diluted, pro forma	\$	0.04	\$ ====	0.02

14

## METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Stock option activity as of June 30, 2006 and changes during the six months ended June 30, 2006 were as follows:

	OPTIONS EXERCISE PRICE V.		EXERCISE PRICE		XERCISE PRICE		VALUE
Balance, December 31, 2005	6,385,810	\$	1.63				
Granted	50,000	\$	2.08				
Exercised and returned	(195,000)	\$	0.72				
Forfeited and expired	(985,267)	\$	2.49				
Balance, June 30, 2006	5,255,543	\$	1.51	\$	7,314,287		
Exercisable, June 30, 2006	3,125,870	\$	1.25	\$	5,397,830		
	==========						

The weighted-average grant-date fair value of options granted during the six months ended June 30, 2006 and 2005 was \$0.65 and \$0.93, respectively. The aggregate intrinsic value in the table above represents the total pretax intrinsic value (the difference between the Company's closing stock price on the last trading day of the first quarter of fiscal 2006 and the exercise price, multiplied by the number of in-the-money options) that would have been received by the option holders had all option holders exercised their options on June 30, 2006. This amount will change based on the fair market value of the Company's stock. Total intrinsic value of options exercised for the six months ended June 30, 2006 and 2005 was approximately \$382,000 and \$1,532,000, respectively. Total fair value of options vested for the six months ended June 30, 2006 and 2005 was approximately \$87,000 and \$101,000, respectively.

As of June 30, 2006, there was \$833,446 of total unrecognized compensation cost related to non-vested stock options, which is expected to be recognized over a weighted-average period of 1.34 years.

The following table summarizes information about stock options outstanding and exercisable at June 30, 2006:

OPTIONS OUTSTANDING					OPTIONS	EXER
EXERCISE PRICE	NUMBER OF OPTIONS	WEIGHTED AVERAGE EXERCISE PRICE	WEIGHTED AVERAGE REMAINING E CONTRACTUAL LIFE	NUMBER OF OPTIONS	WEIGHTED AVERAGE EXERCISE PRICE	WEI CON
\$0.35 - \$1.00 \$1.14 - \$1.98 \$2.05 - \$2.69	2,040,510 2,383,233 631,800	\$ 0.51 \$ 1.82 \$ 2.26	2 7.92	1,990,510 90,785 44,575	0.50 1.78 2.45	

				=======	
	5,255,543	\$ 1.51	5.62	3,125,870	1.25
\$4.00 - \$6.50	200,000	\$ 5.63	0.68	200,000	5.63

Non-vested stock option awards as of June 30, 2006 and changes during the six months ended June 30, 2006 were as follows:

	NUMBER OF SHARES	WEIGHTED AVERAG GRANT-DATE FAIR VALUE	
Non-vested, December 31, 2005 Granted Vested	2,337,782 50,000 (137,075)	\$ \$ \$	0.94 0.65 0.63
Forfeited and expire	(121,034)	\$	1.13
Non-vested, June 30, 2006	2,129,673	\$	0.94

15

## METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

Non-vested restricted stock awards as of June 30, 2006 and changes during the six months ended June 30, 2006 were as follows:

	RESTRICTED SHARES	WEIGHTED AVERAGE GRANT-DATE FAIR VALUE	
Balance, December 31, 2005 Granted Vested Forfeited and expired	60,000  	\$ \$ 2.08 \$ \$	
Balance, June 30, 2006	60,000	\$ 2.08	

In the quarter and six months ended June 30, 2006, there was approximately \$26,000 of compensation costs related to non-vested restricted stock awards. As of June 30, 2006, there was \$98,325 of total unrecognized compensation cost related to non-vested restricted stock awards, which is expected to be recognized over a weighted-average period of 0.79 years.

NOTE A GROUNDING PROJECT FORTH

#### NOTE 4. STOCKHOLDERS' EQUITY

-----

The Company issued 195,000 shares of common stock in connection with the exercise of stock options during the first six months of 2006. In addition, an aggregate of 60,000 shares of restricted common stock were issued to two new members of the Company's Board of Directors upon their appointment to the Board of Directors in the second quarter.

#### NOTE 5. COMMITMENTS AND CONTINGENCIES

\_\_\_\_\_\_

#### LITIGATION

The Company is party to certain claims arising in the ordinary course of business. Management believes that the outcome of these matters will not have a material adverse effect on the financial position or the results of operations of the Company.

-----

#### NOTE 6. BUSINESS SEGMENT INFORMATION

HMO commenced operations effective July 1, 2005.

In 2006, the Company is operating in two segments for purposes of presenting financial information and evaluating performance, the PSN and the HMO. The

SIX MONTHS ENDED JUNE 30, 2006	PSN	HMO	TOTAL
Revenues from external customers	\$101,645,000	\$ 11,336,000	\$112,981,000
Segment gain (loss) before allocated overhead	9,823,000	(4,170,000)	5,653,000
Allocated corporate overhead	1,818,000	1,431,000	3,249,000
Segment gain (loss) after allocated overhead			
and before income taxes	8,005,000	(5,601,000)	2,404,000
Segment assets	19,900,000	16,169,000	36,069,000
SIX MONTHS ENDED JUNE 30, 2005	PSN	НМО	TOTAL
Revenues from external customers	\$ 91,689,000	\$	91,689,000
Segment gain (loss) before allocated overhead	8,027,000	(1,732,000)	6,295,000
Allocated corporate overhead	1,927,000	534,000	2,461,000
Segment gain (loss) after allocated overhead			
and before income taxes	6,100,000	(2,266,000)	3,834,000
Segment assets	22,596,000	3,460,000	26,056,000

16

# METROPOLITAN HEALTH NETWORKS, INC. AND SUBSIDIARIES NOTES TO CONDENSED CONSOLIDATED FINANCIAL STATEMENTS (UNAUDITED)

THREE MONTHS ENDED JUNE 30, 2006	PSN	HMO	TOTAL
Description from subsumal sustances	¢ 50 000 000	¢ ( (4( 000	457 540 000
Revenues from external customers	\$ 50,902,000	\$ 6,646,000	457,548,000
Segment gain (loss) before allocated overhead	5,203,000	(2,242,000)	2,961,000
Allocated corporate overhead	877 <b>,</b> 000	762 <b>,</b> 000	1,639,000
Segment gain (loss) after allocated overhead			
a nd before income taxes	4,326,000	(3,004,000)	1,322,000
THREE MONTHS ENDED JUNE 30, 2005	PSN	НМО	TOTAL
Revenues from external customers	\$ 6,169,000	\$	46,169,000

Segment gain (loss) before allocated overhead	4,239,000	(1,032,000)	3,207,000
Allocated corporate overhead	910,000	304,000	1,214,000
Segment gain (loss) after allocated overhead a			
nd before income taxes	3,329,000	(1,336,000)	1,993,000

17

ITEM 2. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

THE FOLLOWING DISCUSSION SHOULD BE READ IN CONJUNCTION WITH THE COMPANY'S ANNUAL REPORT ON FORM 10-K FOR THE YEAR ENDED DECEMBER 31, 2005, AS WELL AS THE FINANCIAL STATEMENTS AND NOTES THERETO.

#### CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS

Sections of this Quarterly Report contain statements that are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934 (the "Exchange Act"), and the Company intends that such forward-looking statements be subject to the safe harbors created thereby. Statements in this Report containing the words "estimate," "project," "anticipate," "expect," "intend," "believe," "will," "could," "should," "may," and similar expressions may be deemed to create forward-looking statements. Accordingly, such statements, including without limitation, those relating to the Company's future business, prospects, revenues, working capital, liquidity, capital needs, interest costs and income, wherever they may appear in this document or in other statements attributable to the Company, involve estimates, assumptions and uncertainties which could cause actual results to differ materially from those expressed in the forward-looking statements. Specifically, this Quarterly Report contains forward-looking statements, including the following:

- o the PSN's ability to renew the Humana Agreements and maintain the Humana Agreements on favorable terms;
- o the Company's ability to adequately predict and control medical expenses and to make reasonable estimates and maintain adequate accruals for incurred but not reported, or IBNR, claims; and
- o the HMO's ability to renew, maintain or to successfully rebid for its agreement with CMS.

The forward-looking statements reflect the Company's current view about future events and are subject to risks, uncertainties and assumptions. The Company wishes to caution readers that certain important factors may have affected and could in the future affect its actual results and could cause actual results to differ significantly from those expressed in any forward-looking statement. The following important factors could prevent the Company from achieving its goals and cause the assumptions underlying the forward-looking statements and the actual results to differ materially from those expressed in or implied by those forward-looking statements:

- o reductions in government funding of Medicare programs;
- o disruptions in the HMO's or Humana's healthcare provider networks;

- o failure to receive claims processing, billing services, data collection and other information on a timely basis from Humana;
- o future legislation and changes in governmental regulations;
- o increased operating costs;
- o the impact of Medicare Risk Adjustments on payments the Company receives for its managed care operations;
- o loss of significant contracts;
- o general economic and business conditions;
- o increased competition;
- o the relative health of the Company's patients;
- o changes in estimates and judgments associated with our critical accounting policies;
- o federal and state investigations;

18

- o the Company's ability to successfully recruit and retain key management personnel and qualified medical professionals; and
- o impairment charges that could be required in future periods.

Additional information concerning these and other risks and uncertainties is contained in the Company's filings with the Securities and Exchange Commission (the "Commission"), including the section entitled "Risk Factors" in its Annual Report on Form 10-K for the year ended December 31, 2005.

Forward-looking statements should not be relied upon as a prediction of actual results. Subject to any continuing obligations under applicable law or any relevant listing rules, the Company expressly disclaims any obligation to disseminate, after the date of this Quarterly Report on Form 10-Q, any updates or revisions to any such forward-looking statements to reflect any change in expectations or events, conditions or circumstances on which any such statements are based.

## BACKGROUND

Through its provider service network ("PSN") and its health maintenance organization ("HMO"), Metropolitan currently provides healthcare benefits to Medicare beneficiaries in Florida. As of June 1, 2006, the PSN and HMO provided healthcare benefits to approximately 26,000 and 3,100 Medicare Advantage beneficiaries, respectively (collectively, the "Participating Members").

As of June 30, 2006, substantially all of the Company's revenues were directly or indirectly derived from reimbursements generated by Medicare Advantage health plans. As a result, the Company's revenue and profitability are dependent on government funding levels for Medicare Advantage programs.

Provider Service Network

Pursuant to two contracts with Humana, Inc. (the "Humana Agreements"), the second largest participant in the Medicare Advantage program ("Humana"), the PSN

provides, on a non-exclusive basis, healthcare services to Medicare beneficiaries in Flagler and Volusia Counties ("Central Florida") and Palm Beach, Broward and Miami-Dade Counties ("South Florida") who have elected to receive benefits from Humana's Medicare Advantage Plan. As of June 1, 2006, the Humana Agreements covered approximately 19,400 Humana Plan Members (as defined below) in Central Florida and 6,500 Humana Plan Members in South Florida.

The PSN is comprised both of medical practices owned by the Company as well as independently owned medical practices and providers with whom it has contracted ("IPs"). The Company currently owns and operates eight primary care physician practices and a medical oncology physician practice. The Company also contracts with twenty-nine primary care IPs. Through its Humana Agreements, the PSN has established referral relationships with a large number of specialist physicians, ancillary service providers and hospitals throughout South Florida and Central Florida.

Humana directly contracts with the Centers for Medicare and Medicaid Services ("CMS") and is paid a fixed monthly premium payment for each member ("Humana Plan Member") enrolled in Humana's Medicare Advantage Plan. The monthly amount varies by patient, county, age and severity of health status. Pursuant to the Humana Agreements, the PSN provides or arranges for the provision of covered medical services to each Humana Plan Member who selects one of the Company's affiliated providers as his or her primary care physician (a "Humana Participating Member"). In return for the provision of these medical services, the PSN receives from Humana a monthly fee, also known as a "capitated fee", for each Humana Participating Member. The fee rates are established by the contracts between the PSN and Humana and comprise a vast majority of the monthly premiums received by Humana from CMS with respect to Humana Participating Members.

The PSN assumes the full financial responsibility for the provision of all Medicare-covered medical care to Humana Participating Members, including those medical services that the PSN does not itself provide. To the extent the costs of providing such medical care are less than the related premiums receivable from Humana, the PSN generates an operating profit. Conversely, if the medical costs exceed the fees receivable from Humana, the PSN experiences an operating loss.

19

The vast majority of the PSN's revenues come from the Humana Agreements. The Company does receive additional revenue for providing primary care services to non-Humana Plan Members on a fee-for-service basis in the medical practices it owns and operates.

For the three and six months ended June 30, 2006, approximately 88% and 90% of Metropolitan's revenue came from the Humana Agreements, respectively. The Humana Agreements have one-year terms and renew automatically each December 31 for additional one-year terms unless terminated for cause or upon 180 days' prior notice. Failure to maintain the Humana Agreements on favorable terms would adversely affect Metropolitan's results of operations and financial condition.

Health Maintenance Organization

Effective July 1, 2005, METCARE Health Plans, Inc., the Company's wholly owned subsidiary ("HMO"), became licensed as a Medicare Advantage HMO and entered into a contract with CMS (the "CMS Contract") to begin offering Medicare Advantage plans to Medicare beneficiaries in six Florida counties which include the cities of Fort Pierce, Port St. Lucie, Fort Myers, Port Charlotte and Sarasota. The HMO has been marketing its "AdvantageCare" branded plan since July 2005 and, as of June 1, 2006, there were approximately 3,145 enrollees in its plan.

In addition to growth within existing service areas, the HMO has applied to expand its HMO business into additional Florida counties. However, Metropolitan does not intend to provide HMO services in the geographic markets with respect to which the PSN has a contract with Humana. Metropolitan views its HMO business as an extension of its existing core competencies.

The HMO's revenues are generated by premiums consisting of monthly payments per member that are established by the CMS Contract. The HMO recorded its first revenues in the third quarter of fiscal 2005.

The Humana Agreements and the CMS Contract are risk agreements under which the PSN and HMO, respectively, receive monthly payments per Participating Member at a rate established by the agreements, also called a capitated fee. In accordance with the agreements, the total monthly payment is a function of the number of Participating Members, regardless of the actual utilization rate of covered services.

To the extent that the Participating Members require more care than is anticipated, aggregate capitation rates may be insufficient to cover the costs associated with the treatment of such members. If medical expenses exceed the Company's estimates, except in very limited circumstances, it will be unable to increase the premiums it receives under these contracts during the then-current terms.

Relatively small changes in the Company's ratio of medical expense to revenue can create significant changes in its financial results. Accordingly, the failure to adequately predict and control medical expenses and to make reasonable estimates and maintain adequate accruals for incurred but not reported, or IBNR, claims, may have a material adverse effect on the Company's financial condition, results of operations and/or cash flows.

Although the Company has operated as a risk provider since 1997, it has only operated the HMO since July 1, 2005. While the Company's HMO business has continued to grow, such growth has continued to require capital. In the six months ended June 30, 2006, the Company's HMO business generated a \$4.2 million segment loss before allocated overhead and income taxes and projects that in fiscal 2006 its HMO business will generate a loss of \$5.0 million to \$7.0 million before allocated overhead and income taxes. The amount of the loss will be determined by a number of factors including membership, medical utilization and related costs, and the Company's decisions related to expansion and growth efforts. The Company is still not in a position to meaningfully estimate when, if ever, its HMO business will become profitable and/or generate cash from operations and may be required to fund the development and expansion of the HMO business, including any associated losses, for an extended period of time. Nonetheless, the Company anticipates that the on-going development efforts, reserve requirements and operating costs for its still developing HMO business can be funded by the Company's current resources and projected cash flows from operations until at least June 30, 2007.

To successfully operate the HMO, the Company believes it will have to continue its development of the following capabilities, among others: sales and marketing, customer service and regulatory compliance. No assurances can be given that the Company will be successful in operating this segment of its business despite its allocation of a substantial amount of resources for this purpose. If the HMO does not develop as anticipated or planned, the Company may have to devote additional managerial and/or capital resources to the HMO, which could limit the Company's ability to manage and/or grow its PSN. There can be no assurances that, if for any reason, the Company elects to discontinue the HMO business and/or seeks to sell such business, the Company will be able to fully recoup its expenditures to date with respect to the HMO business.

20

#### CRITICAL ACCOUNTING POLICIES

Our significant accounting policies are described in Note 1 of the "Notes to Condensed Consolidated Financial Statements" included in this Form 10-Q. We believe our most critical accounting policies include the policies set forth below.

Use of Estimates, Revenue, Expense and Receivables

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the amounts reported in the accompanying financial statements. The most significant area requiring estimates relates to the PSN's arrangements with Humana. Such estimates are based on knowledge of current events and anticipated future events, and accordingly, actual results may ultimately differ materially from those estimates.

With regard to revenues, expenses and receivables arising from the Humana Agreements, the Company estimates the amounts it believes will ultimately be realizable based in part upon estimates of claims incurred but not reported ("IBNR") and estimates of retroactive adjustments or unsettled costs to be applied by Humana. The IBNR estimates are made by Humana utilizing actuarial methods and are continually evaluated by management of the Company based upon its specific claims experience. It is reasonably possible that some or all of these estimates could change in the near term by an amount that could be material to the financial statements.

From time to time, Humana charges the PSN for certain medical expenses, which the Company believes are erroneous or are not supported by the Humana Agreements. Management's estimate of recovery on these contestations is based upon its judgment and its consideration of several factors including the nature of the contestations, historical recovery rates and other qualitative factors.

During 2005, the Company incurred approximately \$4.0 million of medical costs related to the implantation of certain Implantable Automatic Defibrillators ("AICD's"). CMS directed that the costs of certain of these procedures that met 2005 eligibility requirements be paid by CMS, rather than billed to Medicare Advantage plans. The Company is working with Humana and the related providers to secure reimbursement for these amounts, and estimated a recovery of approximately \$2.2 million at December 31, 2005. Approximately \$379,000 of this amount was collected during the six months ended June 30, 2006, while an additional \$500,000 was written off due to revised guidance issued by CMS in July 2006 regarding the costs payable by CMS in connection with these procedures. Accordingly, related accounts receivable in the accompanying consolidated balance sheets were \$1.3 million and \$2.2 million at June 30, 2006 and December 31, 2005, respectively. It is reasonably possible that this estimate could change in the near term by an amount that could be material to the financial statements.

Included in revenues for the quarter and six months ended June 30, 2006 were estimated amounts payable to the Company as a result of funding increases under the Medicare risk adjustment ("MRA") program. The purpose of the MRA program is to use health status indicators to improve the accuracy of payments and establish incentives for plans to enroll and treat less healthy Medicare beneficiaries. From 2000 to 2003, risk adjustment payments accounted for only 10% of the payment made by CMS to the Medicare health plans, with the remaining 90% based on demographic factors. In 2004 and 2005, the percentage of payment attributable to risk adjustment was increased to 30% and 50%, respectively. The

percentage of payment attributable to risk has increased to 75% in 2006, with the 100% phase-in of risk-adjusted payment anticipated to be completed in 2007. Based on the Company's applicable risk scores, the Company accrued approximately \$3.5 million during the six months ended June 30, 2006 related to incremental revenues anticipated to be received as a result of the MRA funding increases. These amounts, which are included in accounts receivable in the accompanying consolidated balance sheets at June 30, 2006, are expected to be received by the Company in the second half of the year, consistent with the timing of prior year payments. It is reasonably possible that this estimate could change in the near term by an amount that could be material to the financial statements.

Accounting for Prescription Drug Benefits under Medicare Part D

On January 1, 2006, the HMO and the PSN, through the Humana Agreements, began covering prescription drug benefits in accordance with the requirements of Medicare Part D, to the HMO's and PSN's Medicare Advantage members. The benefits covered under Medicare Part D are in addition to the benefits covered by the HMO and the PSN under Medicare Parts A and B.

21

In general, pursuant to Medicare Part D, pharmacy benefits may vary in terms of coverage levels and out-of-pocket costs for beneficiary premiums, deductibles and co-insurance. However, all Part D plans must offer either "standard coverage" or its actuarial equivalent (with out-of-pocket threshold and deductible amounts that do not exceed those of standard coverage). These "defined standard" benefits represent the minimum level of benefits mandated by Congress. In addition to defined standard plans offered by the HMO, the PSN, through the Humana Agreements, offers prescription drug plans containing benefits in excess of the standard coverage limits.

The payment the Company's HMO receives monthly from CMS generally represents its bid amount for providing insurance coverage. It recognizes premium revenue for providing this insurance coverage ratably over the term of its annual contract. However, its CMS payment is subject to 1) risk corridor adjustments and 2) subsidies in order for the HMO and CMS to share the risk associated with financing the ultimate costs of the Part D benefit.

The amount of revenue payable to a plan by CMS is subject to adjustment, positive or negative, based upon the application of risk corridors that compare a plan's revenues targeted in their bids ("target amount') to actual prescription drug costs. Variances exceeding certain thresholds may result in CMS making additional payments to the HMO or require the HMO to refund to CMS a portion of the payments it received. Actual prescription drug costs subject to risk sharing with CMS are limited to the costs that are, or would have been, incurred under the CMS "defined standard" benefit plan ("allowable risk corridor costs"). The Company estimates and recognizes an adjustment to premium revenues related to the risk corridor payment adjustment based upon pharmacy claims experience to date as if the annual contract were to end at the end of each reporting period. Accordingly, this estimate provides no consideration to future pharmacy claims experience. It is reasonably possible that this estimate could change in the near term by an amount that could be material.

Certain subsidies represent reimbursements from CMS for claims the HMO paid for which it assumes no risk, including reinsurance payments and low-income cost subsidies. Claims paid above the out-of-pocket or catastrophic threshold for which the HMO is not at risk are all reimbursed by CMS through the reinsurance subsidy plans. Low-income cost subsidies represent reimbursements from CMS for all or a portion of the deductible, the coinsurance and the co-payment amounts for low-income beneficiaries. The Company accounts for these subsidies as

current liabilities in its balance sheet and as an operating activity in its statement of cash flows. The Company does not recognize premium revenue or claims expense for these subsidies.

The HMO recognizes pharmacy benefit costs as incurred. It has subcontracted the pharmacy claims administration to a third party pharmacy benefit manager.

With regards to PSN, the Company receives Medicare Part D revenue pursuant to the applicable percent of premium provided for in the Humana Agreements. Humana does not provide the Company with a separate accounting for Part D premium and expense. As with its HMO, the Company recognizes pharmacy benefit costs as such costs are incurred by the PSN. With regards to the estimated amount of any risk corridor adjustments, the Company has relied upon estimates provided by Humana to the Company and has recorded a downward adjustment to premium revenue based on these estimates. It is reasonably possible that this estimate could change in the near term by an amount that could be material.

Use of Estimates, Deferred Tax Asset

The Company has recorded a deferred tax asset of approximately \$7.2 million at June 30, 2006. Realization of the deferred tax asset is dependent on generating sufficient taxable income in the future. The amount of the deferred tax asset considered realizable could change in the near term if estimates of future taxable income are modified and those changes could be material (see "Notes to Consolidated Financial Statements," Note 1 - "Use of Estimates, Deferred Tax Asset" and Note 1 - "Income Taxes").

Stock-Based Compensation Expense

Effective January 1, 2006, the Company adopted SFAS 123(R) using the modified prospective transition method. SFAS 123(R) requires the Company to recognize compensation costs related to share-based payment transactions with employees in its financial statements. SFAS 123(R) requires the Company to calculate this cost based on the grant date fair value of the equity instrument. Consistent with its prior disclosures under SFAS 123, the Company elected to calculate the fair value of its employee stock options using the Black-Scholes option pricing model. Based on the Black-Scholes model and its assumptions, the Company recognized stock-based employee compensation expense of approximately \$162,000 and \$364,000 for the quarter and six months ended June 30, 2006, respectively (See "Notes to Condensed Consolidated Financial Statements," Note 3.").

22

SFAS 123(R) does not require the use of any particular option valuation model. Because the Company's stock options have characteristics significantly different from traded options and because changes in the subjective input assumptions can materially affect the fair value estimate, it is possible that existing models may not necessarily provide a reliable measure of the fair value of the Company's employee stock options. It selected the Black-Scholes model based on prior experience with it, its wide use by issuers comparable to the Company, and the Company's review of alternate option valuation models. Based on these factors, the Company believes that the Black-Scholes model and the assumptions it made in applying it provide a reasonable estimate of the fair value of its employee stock options.

The effect of applying the fair value method of accounting for stock options on reported net income for any period might not be representative of the effects for future periods because outstanding options typically vest over a period of several years and additional awards may be made in future periods.

#### RESULTS OF OPERATIONS

The Company recognized revenues of \$57.5 million for the quarter ended June 30, 2006 compared to \$46.2 million in the prior year quarter, an increase of \$11.4 million, or 24.6%. Net income for the quarter ended June 30, 2006 was \$819,000 compared to \$1.2 million for the quarter ended June 30, 2005.

For the six months ended June 30, 2006, the Company recognized revenues of \$113.0 million compared to \$91.7 million in the prior year period, an increase of \$21.3 million, or 23.2%. Net income for the six months ended June 30, 2006 was \$1.5 million compared to \$2.4 million for the six months ended June 30, 2005.

Basic earnings per share were \$0.02 and \$0.03 for the quarters ended June 30, 2006 and 2005, respectively. The weighted average shares outstanding for the quarter increased from 48,745,000 at June 30, 2005 to 49,971,000 in the current year.

For the six months ended June 30, 2006 and 2005, basic earnings per share were \$0.03 and \$0.05, respectively. The weighted average shares outstanding for the six months increased from 48,435,000 at June 30, 2005 to 49,916,000 in the current year.

As discussed above, the Company recognized stock-based employee compensation expense of \$162,000 and \$364,000 for the quarter and six months ended June 30, 2006, respectively, compared to none in the prior year periods.

The current year operations include both the PSN segment and the operations of the Company's start-up Medicare Advantage HMO segment, which began enrolling members effective July 1, 2005. The PSN reported Segment gain before allocated overhead of \$5.2 million and \$9.8 million for the quarter and six months ended June 30, 2006, respectively, compared to \$4.2 million and \$8.0 million for the quarter and six months ended June 30, 2005, respectively. The HMO incurred a Segment loss before allocated overhead of \$2.2 million and \$4.2 million for the quarter and six months ended June 30, 2006, compared to \$1.0 million and \$1.7 million for the quarter and six months ended June 30, 2005, respectively. Formal operations of the HMO business commenced July 1, 2005.

#### MEMBERSHIP

Total Medicare Advantage lives, the number of Medicare beneficiaries cared for in either the PSN or HMO, increased approximately 2,300 members from June 2005 to a membership of over 29,000 in June 2006. June 1, 2006 membership for the PSN and HMO was 25,875 and 3,145, respectively. Member months, the combined total membership for each month of the measurement period, were 86,012 and 79,816 for the 2006 and 2005 quarters, respectively. For the six months periods, member months were 169,462 and 159,366 for 2006 and 2005, respectively. Included in these numbers were approximately 8,441 and 14,373 member months related to the HMO for the quarter and six months ended June 30, 2006, respectively.

During 2005, the Company discontinued its contractual relationship with a number of its South Florida physician practices due to non-compliance with the Company's policies and procedures. These centers accounted for approximately 2,200 and 4,400 member months in the quarter and six months ended June 30, 2005, respectively, Corresponding revenues for these practices for the quarter and six months ended June 30, 2005 were \$1.1 million and \$2.7 million, respectively, while medical expenses attributable to these practices for the same periods were \$1.2 million and \$2.8 million, respectively.

COMPARISON OF THE QUARTERS ENDED JUNE 30, 2006 AND JUNE 30, 2005

#### REVENUES

Revenues for the quarter ended June 30, 2006 increased \$11.4 million, or 24.6%, over the prior year quarter, from \$46.2 million to \$57.5 million. PSN revenues from Humana increased 10.3%, from \$45.8 million to \$50.6 million. Approximately \$6.0 million in incremental quarterly revenues were generated by 2006 premium increases, inclusive of Part D premium, that averaged approximately 13.5% over the prior year quarter. These increases were partially offset by the abovementioned decreases due to discontinued medical practices.

Revenues for the Company's HMO, which began enrolling members in July 2005, amounted to \$6.6 million for the 2006 quarter. Included in this amount was approximately \$658,000 of revenue attributable to Medicare Part D premiums.

The HMO memberships' average risk adjustment factor declined from December 2005 to June 2006 as a result of a large influx of new members in 2006. This decline resulted in decreased average member monthly premiums. The Company believes that the actual average risk adjustment factor for its population during this period was higher and that an increase will be reflected as claims and health data for these new members are entered into the CMS system, which is expected to result in retroactive premium adjustments. The Company cannot estimate the amount of the anticipated increase at this time but believes this amount may be material to the results of the HMO.

#### OPERATING EXPENSES

#### Total Medical Expenses

Medical expenses represent the total costs of providing patient care and are comprised of two components. Direct medical costs represent costs incurred in the PSN and HMO operations that are paid or payable to third parties including physicians, hospitals and ancillary service providers on a capitated or fee for service basis. Other medical costs represents the costs associated with the operations of the Company's wholly owned physician practices and oncology center including salaries and benefits, supplies, malpractice insurance and office related expenses. Medical expenses totaled \$50.9 million and \$41.4 million for the quarters ended June 30, 2006 and 2005, respectively. The Company's medical expense ratio ("MER"), the ratio of total medical expense to revenue, improved to 88.4% in the second quarter of 2006 from 89.6% in the second quarter of 2005, with the Company's PSN reporting a 2006 second quarter MER of 88.1%.

Due to its small membership, the HMO's operations are relatively volatile from a medical utilization standpoint. The second quarter 2006 results were adversely affected by several high-cost hospital admissions, resulting in a MER of 90.7% for the segment. Management expects that volatility will decline as membership grows and that the HMO's MER will decrease in future periods.

All of the Company's Medicare Advantage members are enrolled in plans that include the new prescription drug benefit, or Medicare Part D ("Part D"). With regard to the HMO operations, Part D generated a gross margin of approximately 9.6% in the quarter ended June 30, 2006.

With regard to the PSN business, the accounting for Part D by Humana is integrated with Medicare Parts A and B results. The Company is unable to isolate the discrete Part D margin, however it is management's expectation that Part D will not materially affect its overall MER in 2006 in this business.

Administrative Payroll, Payroll Taxes and Benefits

Administrative payroll, payroll taxes and benefits include salaries and related costs for the Company's executive and administrative staff. For the 2006 second quarter, administrative payroll, payroll taxes and benefits were \$2.6 million, compared to the prior year quarter total of \$1.4 million. The Company's HMO segment accounted for \$605,000 of the incremental current quarter's expense, with an additional \$50,000 due to 401(k) and bonus accruals and \$162,000 attributable to the expensing of stock options. The balance of the increase is due to new hires, salary increases and increased benefit costs.

24

#### Marketing and Advertising

Marketing and advertising expense for the 2006 second quarter was \$1.0 million, compared to an expense of \$156,000 in the prior year quarter. This primarily represents the costs and sales commissions incurred to market and sell the Company's HMO AdvantageCare product.

#### General and Administrative

General and administrative expenses for the second quarter of 2006 amounted to \$2.0 million, an increase of \$606,000 over the prior year's quarter. This increase is primarily attributable to expenses incurred in connection with the HMO, primarily with respect to costs associated with outsourced claims processing and member services, insurance, rents and leases and legal and accounting. Included in the 2006 second quarter's costs were approximately \$144,000 of actuarial, consulting and legal costs related to filing expansion applications and plan bids for 2007's operations.

#### OTHER INCOME AND EXPENSE

Other income and expenses for the 2006 quarter increased \$83,000 over the 2005 quarter. Over the year between the quarters the Company's cash and investment balances increased, as did prevailing interest rates, accounting for a \$151,000 increase in interest and investment income.

COMPARISON OF THE SIX MONTHS ENDED JUNE 30, 2006 AND JUNE 30, 2005

#### REVENUES

Revenues for the six months ended June 30, 2006 increased \$21.3 million, or 23.2%, over the prior year period, from \$91.7 million to \$113.0 million. PSN revenues from Humana increased 11.2%, from \$90.8 million to \$101.0 million. Approximately \$12.5 million in incremental revenues were generated by 2006 premium increases, inclusive of Part D premium, that averaged approximately 14.2% over the prior year period. These increases were partially offset by the abovementioned decreases due to discontinued medical practices.

Revenues for the Company's HMO, which began enrolling members in July 2005, amounted to \$11.3 million for the 2006 period. Included in this amount was approximately \$1.1 million of revenue attributable to Medicare Part D premiums.

The HMO memberships' average risk adjustment factor declined from December 2005 to June 2006 as a result of a large influx of new members in 2006. This decline resulted in decreased average member monthly premiums. The Company believes that the actual average risk adjustment factor for its population during this period was higher and that an increase will be reflected as claims and health data for these new members are entered into the CMS system, which is expected to result in retroactive premium adjustments. The Company cannot estimate the amount of the anticipated increase at this time but believes this amount may be material

to the results of the HMO.

OPERATING EXPENSES

Total Medical Expenses

Medical expenses represent the total costs of providing patient care and are comprised of two components. Direct medical costs represent costs incurred in the PSN and HMO operations that are paid or payable to third parties including physicians, hospitals and ancillary service providers on a capitated or fee for service basis. Other medical costs represents the costs associated with the operations of the Company's wholly owned physician practices and oncology center including salaries and benefits, supplies, malpractice insurance and office related expenses. Medical expenses totaled \$100.4 million and \$82.5 million for the six months ended June 30, 2006 and 2005, respectively. The Company's medical expense ratio ("MER"), the ratio of total medical expense to revenue, improved to 88.9% in the first half of 2006 from 90.0% in the first half of 2005, with the Company's PSN reporting a 2006 six month MER of 88.7%.

25

Due to its small membership, the HMO's operations are relatively volatile from a medical utilization standpoint. The 2006 first half results were adversely affected by several high-cost hospital admissions, resulting in a MER of 90.8% for the segment. Management expects that volatility will decline as membership grows and that the HMO's MER will decrease in future periods.

All of the Company's Medicare Advantage members are enrolled in plans that include the new prescription drug benefit, or Medicare Part D ("Part D"). With regard to the HMO operations, Part D generated a gross margin of approximately 10.7% in the six months ended June 30, 2006.

With regard to the PSN business, the accounting for Part D by Humana is integrated with Medicare Parts A and B results. The Company is unable to isolate the discrete Part D margin, however it is management's expectation that Part D will not materially affect its overall MER in 2006 in this business.

Administrative Payroll, Payroll Taxes and Benefits

Administrative payroll, payroll taxes and benefits include salaries and related costs for the Company's executive and administrative staff. For the six months ended June 30, 2006, administrative payroll, payroll taxes and benefits were \$5.0 million, compared to the prior year total of \$2.7 million. The Company's HMO segment accounted for \$1.1 million of the incremental current year's expense, with an additional \$200,000 due to incremental 401(k) and bonus accruals and \$364,000 attributable to the expensing of stock options. The balance of the increase is due to new hires, salary increases and increased benefit costs.

Marketing and Advertising

Marketing and advertising expense for the six months ended June 30, 2006 was \$2.0 million, compared to \$156,000 in the prior year period. This primarily represents the costs and sales commissions incurred to market and sell the Company's HMO AdvantageCare product.

General and Administrative

General and administrative expenses for the first six months of 2006 amounted to \$3.5 million, an increase of \$810,000 over the prior year period. This increase

is primarily attributable to expenses incurred in connection with the HMO, primarily with respect to costs associated with outsourced claims processing and member services, insurance, rents and leases and legal and accounting. Included in the 2006 period costs were approximately \$157,000 of actuarial, consulting and legal costs related to filing expansion applications and plan bids for 2007's operations.

#### OTHER INCOME AND EXPENSE

Other income and expenses for the six months ended June 30, 2006 increased \$147,000 over the 2005 period. Over the year between periods the Company's cash and investment balances increased, as did prevailing interest rates, accounting for a \$275,000 increase in interest and investment income.

#### LIQUIDITY AND CAPITAL RESOURCES

Total cash and equivalents and short-term investments at June 30, 2006 totaled approximately \$21.3 million as compared to approximately \$15.6 million at December 31, 2005. The Company had a working capital surplus of approximately \$23.0 million as of June 30, 2006, compared to a surplus of approximately \$21.1 million as of December 31, 2005.

The Company received an additional monthly premium payment from CMS in the amount of approximately \$2.6 million, representing premium due for the month of July 2006. This amount is included as advance and unearned premiums on the Company's balance sheet.

The Company's total stockholder equity increased approximately \$1.8 million, from approximately \$29.7 million at December 31, 2005 to approximately \$31.7 million at June 30, 2006.

At June 30, 2006, the Company had no outstanding debt.

26

Net cash provided by operating activities for the six months ended June 30, 2006 was approximately \$6.8 million, of which net income accounted for approximately \$1.5 million. Other large sources of cash from operating activities were:

- o an increase in advance and unearned premiums of \$3.3 million;
- o an increase in estimated medical expenses payable of \$1.9 million;
- o a decrease in deferred income taxes of \$913,000;
- o an increase in accrued expenses of \$449,000;
- o stock-based compensation expense of \$364,000;
- o a decrease in other current assets of \$297,000; and
- o depreciation and amortization of \$215,000.

These sources of cash were partially offset by the following uses of cash:

- o an increase in accounts receivable of \$972,000;
- o an increase in prepaid expenses of \$597,000;
- o a decrease in accounts payable of \$323,000; and
- o a decrease in accrued payroll of \$311,000.

Approximately \$3.4 million of the \$5.2 million balance in accounts receivable at June 30, 2006 was collected in July 2006.

During 2005, the Company incurred approximately \$4.0 million of medical costs related to the implantation of certain Implantable Automatic Defibrillators ("AICD's"). CMS directed that the costs of certain of these procedures that met

2005 eligibility requirements be paid by CMS, rather than billed to Medicare Advantage plans. The Company is working with Humana and the related providers to secure reimbursement for these amounts, and estimated a recovery of approximately \$2.2 million at December 31, 2005. Approximately \$379,000 of this amount was collected during the six months ended June 30, 2006, while an additional \$500,000 was written off due to revised guidance issued by CMS regarding the costs payable by CMS in connection with these procedures.

Net cash used in investing activities for the six months ended June 30, 2006 was approximately \$6.8 million. The Company purchased \$5.7 million of short-term investments, \$313,000 of long-term investments and incurred \$848,000 in capital expenditures during the six month period.

The Company's financing activities for the six months ended June 30, 2006 provided approximately \$140,000 of cash in connection with the issuance of common stock upon the exercise of outstanding options.

On May 6, 2005 the Company executed an unsecured commercial line of credit agreement with a bank, which provided for borrowings and issuance of letters of credit of up to \$1.0 million. The credit line expired on March 31, 2006 and was automatically renewed with a new expiration date of March 31, 2007. The outstanding balance, if any, bears interest at the bank's prime rate. The credit facility requires the Company to comply with certain financial covenants, including a minimum liquidity requirement of \$2.0 million. The availability under the line of credit secures a \$1.0 million letter of credit that the Company has caused to be issued in favor of Humana. As of June 30, 2006, the Company has not utilized this commercial line of credit.

Although the Company has operated as a risk provider since 1997, it has only operated the HMO since July 1, 2005. While the Company's HMO business has continued to grow, such growth has continued to require capital. In the six months ended June 30, 2006, the Company's HMO business generated a \$4.2 million segment loss before allocated overhead and income taxes and projects that in fiscal 2006 its HMO business will generate a loss of \$5.0 million to \$7.0 million before allocated overhead and income taxes. The amount of the loss will be determined by a number of factors including membership, medical utilization and related costs, and the Company's decisions related to expansion and growth efforts. The Company is still not in a position to meaningfully estimate when, if ever, its HMO business will become profitable and/or generate cash from operations and may be required to fund the development and expansion of the HMO business, including any associated losses, for an extended period of time. Nonetheless, the Company anticipates that the on-going development efforts, reserve requirements and operating costs for its still developing HMO business can be funded by the Company's current resources and projected cash flows from operations until at least June 30, 2007.

27

To successfully operate the HMO, the Company believes it will have to continue its development of the following capabilities, among others: sales and marketing, customer service and regulatory compliance. No assurances can be given that the Company will be successful in operating this segment of its business despite its allocation of a substantial amount of resources for this purpose. If the HMO does not develop as anticipated or planned, the Company may have to devote additional managerial and/or capital resources to the HMO, which could limit the Company's ability to manage and/or grow its PSN. There can be no assurances that, if for any reason, the Company elects to discontinue the HMO business and/or seeks to sell such business, the Company will be able to fully recoup its expenditures to date with respect to the HMO business.

In 2004, Metropolitan adopted an investment policy with respect to the investment of its cash and equivalents. The investment policy goal is to obtain the highest yield possible while investing only in highly rated instruments or investments with nominal risk of loss of principal. The investment policy sets forth a list of "Permitted Investments" and provides that the Chief Financial Officer or the Chief Executive Officer must approve any exceptions to the policy.

#### OFF-BALANCE SHEET ARRANGEMENTS

The Company does not have any Off-Balance Sheet Arrangements that have or are reasonably likely to have a current or future effect on the Company's financial condition, changes in financial condition, revenues or expenses, results of operations, liquidity, capital expenditures or capital resources that are material to investors.

#### ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

#### MARKET RISK

Market risk generally represents the risk of loss that may result from the potential change in value of a financial instrument as a result of fluctuations in interest rates and market prices. At June 30, 2006, the Company had only commercial paper, certificates of deposit and cash equivalents invested in high grade, short-term and long-term securities, which are not typically subject to material market risk. The Company has established policies and internal processes related to the management of market risks, which it uses in the normal course of its business operations.

#### INTEREST RATE RISK

The Company believes a change in interest rates would not have a material impact on its financial condition, future results of operations or cash flows.

#### INTANGIBLE ASSET RISK

The Company has a substantial amount of intangible assets. It is required to perform goodwill impairment tests whenever events or circumstances indicate that the carrying value may not be recoverable from estimated future cash flows. As a result of its periodic evaluations, the Company may determine that the intangible asset values need to be written down to their fair values, which could result in material charges that could be adverse to its operating results and financial position. Although at June 30, 2006 the Company believes its intangible assets were recoverable, changes in the economy, the business in which it operates and its own relative performance could change the assumptions used to evaluate intangible asset recoverability. The Company continues to monitor those assumptions and their effect on the estimated recoverability of its intangible assets.

#### EQUITY PRICE RISK

The Company does not own any equity investments, other than in its subsidiaries. As a result, it does not currently have any direct equity price risk.

#### COMMODITY PRICE RISK

The Company does not enter into contracts for the purchase or sale of commodities. As a result, it does not currently have any direct commodity price risk.

2.8

#### ITEM 4. CONTROLS AND PROCEDURES

The Company's management, which includes its Chief Executive Officer and its Chief Financial Officer, conducted an evaluation of the effectiveness of its disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) promulgated under the Exchange Act as of the end of the period covered by this report. Based upon that evaluation, its Chief Executive Officer and Chief Financial Officer concluded that its disclosure controls and procedures are effective to ensure that information required to be disclosed by the Company in the reports that it files or submits under the Exchange Act, is recorded, processed, summarized and reported, within the time periods specified in the SEC's rules and forms, and that such information is accumulated and communicated to its management, including its Chief Executive Officer and Chief Financial Officer, as appropriate, to allow timely decisions regarding required disclosure.

There have been no significant changes made in the Company's internal controls over financial reporting that occurred during its last fiscal quarter that have materially affected or are reasonably likely to materially affect its internal control over financial reporting.

29

#### PART II OTHER INFORMATION

#### ITEM 1. SUMMARY OF LEGAL PROCEEDINGS

The Company is a party to various legal proceedings which are either immaterial in amount to the Company and its subsidiaries or involve ordinary routine litigation incidental to the business of the Company and its subsidiaries. There are no material pending legal proceedings, other than routine litigation incidental to the business of the Company and its subsidiaries, to which the Company or any of its subsidiaries is a party of or which any property of the Company or its subsidiaries is the subject.

#### ITEM 1A. RISK FACTORS

There have been no material changes in our risk factors from those disclosed in our Annual Report on Form 10-K for the fiscal year ended December 31, 2005.

#### ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

NONE

#### ITEM 3. DEFAULTS UPON SENIOR SECURITIES

NONE

## ITEM 4. SUBMISSION OF MATTERS TO A VOTE OF SECURITY HOLDERS

The Annual Meeting of Shareholders (the "Annual Meeting") was held at the Marriott Hotel, 1001 Okeechobee Blvd., West Palm Beach, Florida, on June 8, 2006 for the following purposes:

- o To elect eight members to Metropolitan's Board of Directors to hold office until the next Annual Meeting of Shareholders or until their successors are duly elected and qualified; and
- o To consider and vote upon a proposal to approve of and ratify the selection of Kaufman, Rossin & Co. as the Company's independent auditors for the fiscal year ending December 31, 2006.

The number of outstanding shares of the Company's Common Stock as of April 14, 2006, the record date for the Annual Meeting, was 49,876,526 shares. 43,220,888 shares of Common Stock were represented in person or by proxy at the Annual Meeting.

Pursuant to the Company's Articles of Incorporation, shareholders are entitled to one vote for each share of Common Stock.

The following directors were elected at the Annual Meeting: (i) Michael M. Earley, (ii) Debra A. Finnel, (iii) Martin W. Harrison, M.D., (iv) Barry T. Zeman, (v) Karl M. Sachs, (vi) Eric Haskell, (vii) Robert E. Shields and (viii) David A. Florman.

The following table sets forth the number of votes cast for, against, or withheld for each director nominee, as well as the number of abstentions and broker non-votes as to each such director nominee:

Director Nominee	Votes Cast For	Votes Cast Against	Votes Withheld	Abstentions	BrokerNon- Votes
Michael M. Earley	43,122,578	_	98,310		_
Debra A. Finnel	43,109,938	_	110,950	-	_
Martin W. Harrison	39,265,100	_	3,955,788	_	_
Barry T. Zeman	41,601,550	_	1,619,338	_	_
Karl M. Sachs	38,366,434	_	4,854,454	_	_
Eric Haskell	43,013,142	_	207,746	_	_
Robert E. Shields	43,129,678		91,210		_
David A. Florman	43,131,678	_	89,210	_	_

30

With respect to the proposal to approve of and ratify the selection of Kaufman, Rossin & Co. as the Company's independent registered public accountants for the fiscal year ending December 31, 2006: (i) 43,119,971 votes were cast for such proposal, (ii) 95,860 votes were cast against such proposal and (iii) 5,057 shares abstained from voting on such proposal. No votes were withheld nor were there any broker non-votes with respect to such proposal. Accordingly, the proposal to approve of and ratify Kaufman, Rossin & Co. as the Company's independent registered public accountants for the fiscal year ending December 31, 2006, was approved by the shareholders.

#### ITEM 5. OTHER INFORMATION

NONE

ITEM 6. EXHIBITS

- 3.1 Articles of Incorporation, as amended (1)
- 3.2 Amended and Restated Bylaws (2)
- 10.1 Physician Practice Management Participation Agreement, dated August 2, 2001, between Metropolitan of Florida, Inc. and Humana, Inc. (3)
- 10.2 Letter of Agreement, dated February 2003, between Metropolitan of Florida, Inc. and Humana, Inc. (4)
- 10.3 Physician Practice Management Participation Agreement, dated December 1,1998, between Metcare of Florida, Inc. and Humana, Inc. (9)
- 10.4 Supplemental Stock Option Plan (5)
- 10.5 Omnibus Equity Compensation Plan (6)
- 10.6 Amended and Restated Employment Agreement between Metropolitan and Michael
   M. Earley dated January 3, 2005 (8)
- 10.7 Amended and Restated Employment Agreement between Metropolitan and David S. Gartner dated January 3, 2005 (8)
- 10.8 Amended and Restated Employment Agreement between Metropolitan and Roberto L. Palenzuela dated January 3, 2005 (8)
- 10.9 Amended and Restated Employment Agreement between Metropolitan and Debra
  A. Finnel dated January 3, 2005 (8)
- 10.10 Employment Agreement between Metcare of Florida, Inc. and Jose A. Guethon,  $\text{M.D.}\ (9)$
- 10.11 Form of Option Award Agreement for Option Grants to Directors pursuant to the Omnibus Compensation Plan (9)
- 10.12 Form of Option Award Agreement for Option Grants to Key Employees pursuant to the Omnibus Compensation Plan (9)
- 10.13 Form of Option Award Agreement for Option Grants to Employees pursuant to the Omnibus Compensation Plan (9)
- 10.14 Agreement between Metcare of Florida, Inc. and the Centers for Medicare and Medicaid Services (10)
- 10.15 Code of Business Conduct and Ethics (9)
- 31.1 Certification of the Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\*
- 31.2 Certification of the Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002\*
- 32.1 Certification of the Chief Executive Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\*\*
- 32.2 Certification of the Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002\*\*

-----

 $\star\star$ furnished herewith

- (1) Incorporated by reference to Metropolitan's Registration Statement on Form 8-A12B filed with the Commission on November 19, 2004 (No. 001-32361).
- (2) Incorporated by reference to Metropolitan's Current Report on Form 8-K filed with the Commission on September 30, 2004.
- (3) Incorporated by reference to Metropolitan's Amendment to Registration Statement on Form SB-2/A filed with the Commission on August 2, 2001 (No. 333-61566). Portions of this document were omitted and were filed separately with the SEC on or about August 2, 2001 pursuant to a request for confidential treatment.

31

- (4) Incorporated by reference to Metropolitan's Amendment to Annual Report for the fiscal year ended December 31, 2003 on Form 10-K/A filed with the Commission on July 28, 2004. Portions of this document have been omitted and were filed separately with the SEC on July 28, 2004 pursuant to a request for confidential treatment.
- (5) Incorporated by reference to Metropolitan's Amendment to Annual Report for

<sup>\*</sup> filed herewith

- the fiscal year ended December 31, 2003 on Form 10-K/A filed with the Commission on July 28, 2004.
- (6) Incorporated by reference to Metropolitan's Registration Statement on Form S-8 filed with the Commission on February 24, 2005 (No. 333-122976).
- (7) Incorporated by reference to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2003, as filed with the Commission on March 22, 2004.
- (8) Incorporated by reference to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2004, as filed with the Commission on March 22, 2005.
- (9) Incorporated by reference to the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2005, as filed with the Commission on March 22, 2006.
- (10) Incorporated by reference to the Company's Quarterly Report on Form 10-Q for the fiscal quarter ended March 31, 2006, as filed with the Commission on May 15, 2006.

32

#### SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the Undersigned thereunto duly authorized.

#### Registrant

Date: August 8, 2006 METROPOLITAN HEALTH NETWORKS, INC.

/s/ Michael M. Earley

Michael M. Earley Chairman and

Date: August 8, 2006 Chief Executive Officer

/s/ David S. Gartner

David S. Gartner Chief Financial Officer